<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>3(Suppl 2)</volume><submitter>Dillman R</submitter><journal>Journal for immunotherapy of cancer</journal><pagination>P202-P202</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4649581</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines</pubmed_title><pmcid>PMC4649581</pmcid><pubmed_authors>Dillman R</pubmed_authors><pubmed_authors>Burtzo D</pubmed_authors><pubmed_authors>Amatruda T</pubmed_authors><pubmed_authors>Carbonell D</pubmed_authors><pubmed_authors>Cornforth A</pubmed_authors><pubmed_authors>Semeniuk G</pubmed_authors><pubmed_authors>McClay E</pubmed_authors><pubmed_authors>DePriest C</pubmed_authors><pubmed_authors>Haskins C</pubmed_authors><pubmed_authors>Weber R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens from autologous melanoma tumor cell lines</name><description/><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Jan</publication><modification>2025-04-26T19:31:01.974Z</modification><creation>2025-04-06T16:05:09.049Z</creation></dates><accession>S-EPMC4649581</accession><cross_references/></HashMap>